BRCA1 and pancreatic neoplasm: In classically BRCA-associated tumors, such as breast, ovarian, prostate, and pancreas cancers, BRCA1/2 behave as drivers, exhibiting zygosity-dependence, selection for biallelic inactivation, and potential benefit from PARP inhibition6.